Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Oct 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well different chemotherapy and targeted therapies work for patients with advanced breast cancer who also have fluid buildup in the chest (hydrothorax) and abdomen (ascites). The goal is to use special lab-grown models called organoids, which mimic the patient's tumors, to test how sensitive these tumors are to various treatments. By doing this, the researchers hope to find more effective and personalized treatment options for patients who often have limited choices due to their disease's complexity and past treatments.

To be eligible, participants should be between 18 and 70 years old, have confirmed metastatic breast cancer with tumor cells present in the fluid buildup, and have a good overall health status. They should also have normal liver and kidney function. The study is currently recruiting participants, and those who join can expect to undergo tests using their organoid models to see how their cancer responds to different drugs, helping to guide their treatment plan. This trial aims to improve treatment outcomes and reduce unnecessary side effects for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent form and willingness to participate in the clinical study.
• • 2. patients aged between 18 and 70 years old.
• • 3. Confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab.
• • 4. ECOG performance status score of 0-1.
• • 5. No significant abnormalities in liver and kidney function (BIL \<1.5-fold upper limit of normal (ULN)；ALT\<2.5×ULN; AST\<2.5×ULN；Crea≤1×ULN).
• Exclusion Criteria:
• • 1.Patients not suitable for chemotherapy and target therapy